...
首页> 外文期刊>Anaerobe >Emergence of fluoroquinolone-resistant Propionibacterium acnes caused by amino acid substitutions of DNA gyrase but not DNA topoisomerase
【24h】

Emergence of fluoroquinolone-resistant Propionibacterium acnes caused by amino acid substitutions of DNA gyrase but not DNA topoisomerase

机译:DNA旋转酶而不是DNA拓扑异构酶的氨基酸取代引起的耐氟喹诺酮类痤疮丙酸杆菌的出现

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

With the aim of elucidating the mechanisms of fluoroquinolones resistance in Propionibacterium acnes, we determined the susceptibility of fluoroquinolones in 211 isolates from patients with acne vulgaris. We identified five isolates (2.4%) with reduced susceptibility to nadifloxacin (minimum inhibitory concentration >= 4 mu g/ml). Determination of the sequences of the DNA gyrase (gyrA and gyrB) and DNA topoisomerase (parC and parE) genes showed the amino acid substitutions Ser101Leu and Asp105Gly of GyrA in four and one of the isolates, respectively. In vitro mutation experiments showed that low-level fluoroquinolone-resistant mutants with the Ser101Leu or Asp105Gly substitution in GyrA could be obtained from selection with ciprofloxacin and levofloxacin. The pattern of substitution (Ser101Trp in GyrA) caused by nadifloxacin selection was different from that induced by the other fluoroquinolones. In the isolation of further high-level resistant mutants, acquisition of another amino acid substitution of GyrB in addition to those of GyrA was detected, but there were no substitutions of ParC and ParE. In addition, the mutant prevention concentration and mutation frequency of nadifloxacin were lowest among the tested fluoroquinolones. The growth of the Ser101Trp mutant was lower than that of the other mutants. Our findings suggest that the Ser101Trp mutant of P. acnes emerges rarely and disappears immediately, and the risk for the prevalence of fluoroquinolones-resistant P. acnes differs according to the GyrA mutation type. To our knowledge, this study is the first to demonstrate the mechanisms of resistance to fluoroquinolones in P. acnes. (C) 2016 Elsevier Ltd. All rights reserved.
机译:为了阐明痤疮丙酸杆菌中氟喹诺酮类耐药的机制,我们确定了寻常性痤疮患者211株分离物中氟喹诺酮类药物的敏感性。我们鉴定了对纳地沙星敏感性降低(最低抑菌浓度> = 4μg / ml)的五种分离株(2.4%)。对DNA促旋酶(gyrA和gyrB)和DNA拓扑异构酶(parC和parE)基因的序列测定表明,分别在四种和一种分离物中,GyrA的氨基酸取代Ser101Leu和Asp105Gly。体外突变实验表明,可以通过环丙沙星和左氧氟沙星的筛选获得在GyrA中具有Ser101Leu或Asp105Gly取代的低水平耐氟喹诺酮类突变体。纳迪沙星选择引起的取代模式(GyrA中的Ser101Trp)与其他氟喹诺酮类药物引起的取代模式不同。在分离进一步的高水平抗性突变体时,除GyrA的氨基酸外,还检测到GyrB的另一个氨基酸取代,但没有ParC和ParE的取代。另外,纳氟沙星的突变预防浓度和突变频率在所测试的氟喹诺酮类中最低。 Ser101Trp突变体的生长低于其他突变体。我们的发现表明,痤疮丙酸杆菌的Ser101Trp突变很少出现并立即消失,并且耐氟喹诺酮类痤疮丙酸杆菌的流行风险因GyrA突变类型而异。据我们所知,这项研究是第一个证明痤疮丙酸杆菌对氟喹诺酮类药物具有抗药性的机制。 (C)2016 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号